Who should own SBOM-based remediation decisions in a medical device programme?

How SBOM remediation ownership should be structured in a medical device programme

SBOM-based remediation is not just a vulnerability intake function. In a medical device setting, it crosses software engineering, product security, quality management, regulatory affairs, and legal because the same component issue can affect firmware integrity, patient safety, release readiness, disclosure timing, and field support obligations. The right owner is therefore the programme-level governance layer, with technical execution distributed to the teams that own the affected product and the decision criteria.

A useful way to think about ownership is that engineering owns the fix path, security owns prioritisation and exposure analysis, quality owns change control and evidence, regulatory owns submission and reporting impact, and legal owns disclosure and contractual risk. That split prevents a purely technical team from making decisions that quietly change certification posture or post-market obligations.

In practice, the owner should not be “whoever found the issue” or “who can patch fastest.” The owner should be the function that can convene the decision, force closure across the required disciplines, and keep the remediation record defensible for auditors, regulators, and customers.

What decisions belong to which function

Remediation decisions usually break into five distinct questions: is the component actually exposed in this product, is there a safety or security consequence, what fix is available, does the change need formal verification, and what external notification or customer action is required. Those questions cannot be answered by one department alone without creating blind spots.

Engineering should decide how the issue is removed, whether by upgrade, replacement, configuration change, backport, or compensating control. Security should decide whether the finding is exploitable in the deployed context, whether the exposure is material, and whether the issue belongs in the active remediation queue. Quality should decide what testing, traceability, and release evidence are required before the change can ship. Regulatory and legal should decide whether the change affects submissions, complaint handling, field safety notices, disclosure language, or customer commitments.

If the programme already has a formal vulnerability management process, SBOM findings should flow through that process, but the final disposition still needs product and compliance ownership. That is especially important when a fix is not technically trivial and the team must choose between immediate patching, delayed release, or a documented exception with compensating controls.

For component-specific response planning, teams often pair SBOM review with supply-chain and vulnerability intelligence sources such as OpenSSF and the CISA Known Exploited Vulnerabilities Catalog when deciding whether a finding is merely theoretical or demands immediate action.

Why medical device programmes need shared ownership, not a single gatekeeper

Medical device remediation has a stronger governance burden than ordinary enterprise software because the consequences can extend beyond cyber exposure into patient harm, regulatory scrutiny, and product lifecycle decisions. A single gatekeeper may be able to assign tasks, but cannot legitimately own every implication that follows from a vulnerable dependency in a safety-relevant product.

The programme also has to preserve accountability for the release decision itself. If a fix is merged but not validated, or validated but not assessed for regulatory impact, the organisation may create a new risk while trying to reduce the original one. Shared ownership avoids that failure mode by forcing the decision to be evaluated as a product issue, not just a security ticket.

That governance model is also easier to defend after the fact. When a finding escalates to a customer communication, a field correction, or a delayed release, the organisation needs a record that shows who assessed technical risk, who approved the change path, who confirmed evidence, and who reviewed external obligations.

For organisations building the wider programme around product and supplier risk, the SBOM process sits naturally beside supplier assurance and vulnerability triage disciplines, rather than inside a single engineering backlog.

What good looks like in the operating model

Good ownership is explicit, documented, and decision-based. The programme should define one accountable coordinator for each SBOM finding, but that person should be empowered to route the issue to engineering, security, quality, regulatory, and legal decision-makers before closure. A simple “remediate or accept” choice is usually too coarse for a medical device context.

The most effective model uses a short decision record for each material finding: what component is affected, whether the device use case is exposed, whether the issue changes safety or support posture, what remediation path was selected, and what evidence supports the release or exception. That record becomes the basis for internal review and external defensibility.

When the analysis shows active exploitation or confirmed exposure, prioritisation should follow the same logic used for known exploited weaknesses, with urgency driven by field exposure and product criticality. In that situation, the remediation owner should accelerate cross-functional review rather than treating the issue as a normal backlog item.

Medical device teams that need a broader view of shared accountability can also anchor the process in healthcare-specific security governance, such as Healthcare Identity Security Guide, which reflects how regulated healthcare environments often require more than a single technical owner to make risk decisions durable.

Practitioner Guidance

What to prioritise: assign one accountable programme owner, but require engineering, security, quality, regulatory, and legal sign-off for any SBOM finding that can change release status, field support, or disclosure obligations.

What to verify: before trusting closure, verify that the remediation record states the exposure context, the chosen fix path, the validation evidence, and whether any customer, regulator, or support action is still pending.

Decision rule: if the finding can affect patient safety, regulatory posture, or deployed-device support, treat it as a cross-functional product decision, not a security-only ticket.

Practitioner takeaway: the right owner is the person who can force a complete decision, but the right authority is shared, because SBOM remediation in medical devices changes both technical risk and regulated product obligations.

Related resources from NHI Mgmt Group

• Who should own device risk decisions in an IAM programme?
• Who should own lifecycle-based verification decisions in a fintech programme?
• Who should own device trust decisions in a BYOD programme?
• Who should own risk-based remediation decisions?